» Articles » PMID: 37034537

Treatment Goal Attainment for Secondary Prevention in Coronary Patients with or Without Diabetes Mellitus - Polish Multicenter Study POLASPIRE

Abstract

Introduction: Cardiovascular disease is still a leading cause of death in Poland and across Europe. The aim of this study was to assess the attainment of the main treatment goals for secondary cardiovascular prevention in coronary patients with or without diabetes mellitus (DM) in Poland.

Material And Methods: The study group included 1026 patients (65.5 ±9 y.o.; males: 72%) included at least 6 months after the index hospitalisation for myocardial infarction, unstable angina, elective percutaneous coronary intervention or coronary artery bypass surgery. The target and treatment goals were defined according to the 2016 European Society of Cardiology guidelines on cardiovascular prevention.

Results: Patients with DM ( = 332; 32%) were slightly older compared to non-diabetic ( = 694) individuals (67.2 ±7 vs. 64.6 ±9 years old; < 0.0001). The DM goal was achieved in 196 patients (60%). The rate of primary (LDL: 51% vs. 35%; < 0.0001) and secondary (non-HDL: 56% vs. 48%; < 0.02) goal attainment was higher in DM(+) compared to DM(-) patients. The rate of target blood pressure was lower in DM(+) than in normoglycemic patients (52% vs. 61% at < 140/90 mm Hg, < 0.01. As expected, goal achievement of normal weight (9.5% vs. 19%; < 0.0001) and waist circumference (7% vs. 15%; < 0.001) was lower in diabetic patients and the rate of regular physical activity was similar (DM+ 12% vs. DM- 14%; = ns). Finally, there was no difference in active smokers (DM+ 23% vs. DM- 22%; = ns).

Conclusions: Great majority of Polish patients in secondary prevention do not achieve treatment goals. Although lipid goals attainment is better in DM and the rate of smokers is similar, the management of all risk factors needs to be improved.

Citing Articles

Low Attainment of Treatment Targets for Cardiovascular Risk Factors in Indonesian Adults With Established Coronary Artery Disease.

Arsyad D, Qalby N, Qanitha A, Mappangara I, Milayanti W, Wahiduddin J Eval Clin Pract. 2025; 31(1):e14311.

PMID: 39803729 PMC: 11726404. DOI: 10.1111/jep.14311.


Intragastric botulinum toxin injection: a promising alternative for obesity treatment?.

Balbaloglu H, Tasdoven I, Yorgancioglu I Arch Med Sci. 2024; 20(5):1400-1406.

PMID: 39649282 PMC: 11623158. DOI: 10.5114/aoms/178334.


.

El Ayech Boudiche F, Boudiche S, Othmani S, Mehri H, Larbi M, Yaakoub A Tunis Med. 2024; 102(3):151-156.

PMID: 38545710 PMC: 11358825. DOI: 10.62438/tunismed.v102i3.4713.


Lipid-Lowering Treatment and the Lipid Goals Attainment in Patients with a Very High Cardiovascular Risk.

Lis A, Lis P, Lowicka W, Grabarczyk M, Wita M, Zarczynski P J Cardiovasc Dev Dis. 2023; 10(8).

PMID: 37623342 PMC: 10456080. DOI: 10.3390/jcdd10080329.


Recollection of Physician Information about Risk Factor and Lifestyle Changes in Chronic Coronary Syndrome Patients.

Sinnadurai S, Sowa P, Jankowski P, Gasior Z, Kosior D, Haberka M Int J Environ Res Public Health. 2022; 19(11).

PMID: 35682001 PMC: 9180913. DOI: 10.3390/ijerph19116416.


References
1.
Haberka M, Stolarz-Skrzypek K, Biedron M, Szostak-Janiak K, Partyka M, Olszanecka-Glinianowicz M . Obesity, Visceral Fat, and Hypertension-Related Complications. Metab Syndr Relat Disord. 2018; 16(10):521-529. DOI: 10.1089/met.2018.0062. View

2.
Hall J, do Carmo J, da Silva A, Wang Z, Hall M . Obesity, kidney dysfunction and hypertension: mechanistic links. Nat Rev Nephrol. 2019; 15(6):367-385. PMC: 7278043. DOI: 10.1038/s41581-019-0145-4. View

3.
Kotseva K, De Backer G, De Bacquer D, Ryden L, Hoes A, Grobbee D . Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: Results from the European Society of Cardiology ESC-EORP EUROASPIRE V registry. Eur J Prev Cardiol. 2019; 26(8):824-835. DOI: 10.1177/2047487318825350. View

4.
Piepoli M, Hoes A, Agewall S, Albus C, Brotons C, Catapano A . 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by.... Eur Heart J. 2016; 37(29):2315-2381. PMC: 4986030. DOI: 10.1093/eurheartj/ehw106. View

5.
De Lorenzo A, Carazza M, Lima R . All-cause mortality of metabolically healthy or unhealthy obese: risk stratification using myocardial perfusion imaging. Arch Med Sci Atheroscler Dis. 2019; 3:e90-e95. PMC: 6374568. DOI: 10.5114/amsad.2018.76865. View